Reckitt Benckiser Group (LON:RB) had its price target lifted by Goldman Sachs Group from GBX 7,025 ($91.79) to GBX 7,090 ($92.64) in a report issued on Tuesday. Goldman Sachs Group currently has a neutral rating on the stock.
A number of other analysts also recently commented on the company. Liberum Capital reaffirmed a buy rating and set a GBX 7,600 ($99.31) price target on shares of Reckitt Benckiser Group in a research report on Tuesday. UBS Group reaffirmed a neutral rating and set a GBX 6,300 ($82.32) price target (down from GBX 6,400 ($83.63)) on shares of Reckitt Benckiser Group in a research report on Friday, October 26th. JPMorgan Chase & Co. reaffirmed an overweight rating and set a GBX 9,000 ($117.60) price target on shares of Reckitt Benckiser Group in a research report on Thursday, October 25th. Morgan Stanley reaffirmed a buy rating on shares of Reckitt Benckiser Group in a research report on Tuesday, October 16th. Finally, Sanford C. Bernstein set a GBX 8,200 ($107.15) price target on Reckitt Benckiser Group and gave the company a buy rating in a research report on Thursday, October 4th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the stock. Reckitt Benckiser Group currently has an average rating of Hold and an average price target of GBX 6,999.47 ($91.46).
Shares of RB opened at GBX 6,326 ($82.66) on Tuesday. Reckitt Benckiser Group has a 12 month low of GBX 5,562 ($72.68) and a 12 month high of GBX 8,110.43 ($105.98).
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Recommended Story: What is the Dividend Aristocrat Index?
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.